Home News Expanding our imaging capabilities, introducing PerkinElmer’s Vectra® Polaris™

Expanding our imaging capabilities, introducing PerkinElmer’s Vectra® Polaris™

Aquila are very pleased to announce that we have recently acquired PerkinElmer’s Vectra® Polaris™ Automated Quantitative Pathology Imaging System, allowing us to visualise, analyse, quantify and phenotype immune cells in situ in FFPE tissue sections.

The system integrates multispectral imaging and automated slide scanning, allowing up to 6 markers (plus nuclear counterstain) to be imaged from one section (7-plex), conserving precious tissue and providing valuable data.

To find out more about PerkinElmer’s Vectra® Polaris™ Automated Quantitative Pathology Imaging System, click here.

Get in touch today to find out how our customised specialist multiplex histology panels and human tissue sourcing services can complement your pre-clinical and clinical programs of work.

CD8/CD4/CD163/PD-L1/CD68/Pan CK protein expression in colorectal carcinoma (CRC) stained by IF (with Opal™ Multiplex Detection Reagents using the Vectra® Polaris™ from Perkin Elmer).

Contact